30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Galera Therapeutics Inc (GRTX)

Track

The most recent insider trading activity occurred on November 20, 2025, with a proposed sale and a sale transaction by Mel Sorensen, totaling 140,000 shares. Prior to this, significant buying activity was observed in late 2024 and early 2024, primarily by Yair Schneid and Nancy T. Chang. The last reported insider transaction was a proposed sale on November 20, 2025.
Stock chart
Ticker: GRTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Sorensen Mel
President and CEO
2 sales — total 2,807 USD
Sale 20 Nov 2025
Value US$464,447.01 | Price 235.78 | Shares 3,343
Proposed sale 20 Nov 2025
Value US$4,580,759.36 | Price 289.73 | Shares 816
Buy 30 Dec 2024
Value US$4,740,093.00 | Price 358.69 | Shares 63,773
Sale 16 Aug 2024
Value US$4,825.08 | Price 0.07 | Shares 67,015
Proposed sale 16 Aug 2024
Value US$4,825.08 | Price 0.07 | Shares 67,015
Buy 8 Feb 2024
Value US$25,650.00 | Price 0.17 | Shares 150,000
Buy 7 Feb 2024
Value US$25,935.00 | Price 0.17 | Shares 150,000
Buy 7 Feb 2024
Value US$4,250.00 | Price 0.17 | Shares 25,000
Buy 6 Feb 2024
Value US$5,025.00 | Price 0.20 | Shares 25,000
Buy 5 Feb 2024
Value US$17,921.97 | Price 0.18 | Shares 97,402
Buy 30 Jan 2024
Value US$60,635.00 | Price 0.18 | Shares 335,000
Buy 29 Jan 2024
Value US$27,000.00 | Price 0.18 | Shares 150,000
Buy 16 Mar 2023
Value US$24,717.00 | Price 2.25 | Shares 11,000
Buy 13 Mar 2023
Value US$19,593.00 | Price 1.96 | Shares 10,000
Buy 10 Mar 2023
Value US$168,120.00 | Price 1.68 | Shares 100,000
Buy 17 Dec 2021
Value US$54,804.00 | Price 2.74 | Shares 20,000
Planned sale 1 Sep 2021
Value US$404,498.10 | Price 8.47 | Shares 47,756
Buy 15 Jun 2021
Value US$91,300.00 | Price 9.13 | Shares 10,000
Buy 2 Jun 2021
Value US$86,511.00 | Price 8.65 | Shares 10,000
Buy 1 Jun 2021
Value US$34,741.29 | Price 8.59 | Shares 4,045
Buy 1 Jun 2021
Value US$86,381.00 | Price 8.64 | Shares 10,000
Buy 28 May 2021
Value US$86,410.00 | Price 8.64 | Shares 10,000
Sale 18 Feb 2021
Value US$5,290,000.00 | Price 10.58 | Shares 500,000
Buy 13 Nov 2020
Value US$23,771.26 | Price 10.22 | Shares 2,325
Sale 13 Nov 2020
Value US$103,197.00 | Price 10.32 | Shares 10,000
Sale 12 Nov 2020
Value US$100,627.00 | Price 10.06 | Shares 10,000
Planned sale 26 Oct 2020
Value US$33,660.00 | Price 15.00 | Shares 2,244
Sale 15 Oct 2020
Value US$4,950,000.00 | Price 11.00 | Shares 450,000
Planned sale 6 Oct 2020
Value US$126,432.00 | Price 12.00 | Shares 10,536
Planned sale 5 Oct 2020
Value US$1,200.00 | Price 12.00 | Shares 100
Sale 19 Jun 2020
Value US$8,260,824.00 | Price 8.25 | Shares 1,001,312
Sale 18 Jun 2020
Value US$8,136.00 | Price 9.04 | Shares 900
Sale 17 Jun 2020
Value US$42,845.94 | Price 9.27 | Shares 4,622
Sale 16 Jun 2020
Value US$79,980.00 | Price 9.30 | Shares 8,600
Sale 15 Jun 2020
Value US$55,784.20 | Price 9.05 | Shares 6,164
Sale 12 Jun 2020
Value US$13,785.00 | Price 9.19 | Shares 1,500
Sale 11 Jun 2020
Value US$66,312.00 | Price 9.21 | Shares 7,200
Sale 10 Jun 2020
Value US$80,712.72 | Price 9.46 | Shares 8,532
Sale 9 Jun 2020
Value US$65,660.00 | Price 9.38 | Shares 7,000
Sale 8 Jun 2020
Value US$54,665.94 | Price 9.66 | Shares 5,659
Sale 5 Jun 2020
Value US$83,578.32 | Price 9.66 | Shares 8,652
Sale 4 Jun 2020
Value US$39,040.40 | Price 9.55 | Shares 4,088
Sale 3 Jun 2020
Value US$50,934.24 | Price 9.78 | Shares 5,208
Sale 2 Jun 2020
Value US$54,875.92 | Price 9.68 | Shares 5,669
Planned sale 26 May 2020
Value US$8,304.00 | Price 12.00 | Shares 692
Planned sale 21 May 2020
Value US$14,088.00 | Price 12.00 | Shares 1,174
Planned sale 20 May 2020
Value US$11,628.00 | Price 12.00 | Shares 969
Planned sale 12 May 2020
Value US$8,052.00 | Price 12.00 | Shares 671
Planned sale 11 May 2020
Value US$2,220.00 | Price 12.00 | Shares 185
Planned sale 8 May 2020
Value US$61,224.00 | Price 12.00 | Shares 5,102
Planned sale 7 May 2020
Value US$24,709.44 | Price 12.00 | Shares 2,059
Planned sale 6 May 2020
Value US$17,868.00 | Price 12.00 | Shares 1,489
Planned sale 5 May 2020
Value US$37,258.24 | Price 12.16 | Shares 3,064
Buy 13 Dec 2019
Value US$39,138.80 | Price 9.78 | Shares 4,000
Buy 12 Nov 2019
Value US$233,076.00 | Price 12.00 | Shares 19,423
Buy 12 Nov 2019
Value US$1,165,572.00 | Price 12.00 | Shares 97,131
Buy 12 Nov 2019
Value US$631,920.00 | Price 12.00 | Shares 52,660
Buy 12 Nov 2019
Value US$969,432.00 | Price 12.00 | Shares 80,786
Buy 12 Nov 2019
Value US$6,000,000.00 | Price 12.00 | Shares 500,000
Buy 12 Nov 2019
Value US$233,076.00 | Price 12.00 | Shares 19,423
Buy 12 Nov 2019
Value US$1,165,572.00 | Price 12.00 | Shares 97,131
Buy 12 Nov 2019
Value US$631,920.00 | Price 12.00 | Shares 52,660
Buy 12 Nov 2019
Value US$969,432.00 | Price 12.00 | Shares 80,786
Buy 12 Nov 2019
Value US$9,000,000.00 | Price 12.00 | Shares 750,000
Buy 12 Nov 2019
Value US$4,999,992.00 | Price 12.00 | Shares 416,666
Buy 12 Nov 2019
Value US$3,000,000.00 | Price 12.00 | Shares 250,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-24 2025-11-20 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
3,343 +1.0%
235.78
US$464,447 		3,343 +1.0% 235.78 US$464,447
2025-11-20 2025-11-20 PrS Proposed sale
2.6
Sorensen Mel

Officer

Officer
816
289.73
US$4,580,759 		816 289.73 US$4,580,759
2025-01-02 2024-12-30 B Purchase
CHANG NANCY T
Non-Executive Director Large shareholder
63,773 +36.8%
358.69
US$4,740,093 		63,773 +36.8% 358.69 US$4,740,093
2024-08-20 2024-08-16 S Sale
2.6
Sorensen Mel

President and CEO

Executive Director
67,015 -20.2%
0.07
US$4,825 		67,015 -20.2% 0.07 US$4,825
2024-08-16 2024-08-16 PrS Proposed sale
2.6
Sorensen Mel

Officer; Director

Executive Director
67,015
0.07
US$4,825 		67,015 0.07 US$4,825
2024-02-26 2024-02-08 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,650 		150,000 +1.9% 0.17 US$25,650
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +1.9%
0.17
US$25,935 		150,000 +1.9% 0.17 US$25,935
2024-02-26 2024-02-07 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.17
US$4,250 		25,000 +0.3% 0.17 US$4,250
2024-02-26 2024-02-06 B Purchase
2.7
Schneid Yair
Large shareholder
25,000 +0.3%
0.20
US$5,025 		25,000 +0.3% 0.20 US$5,025
2024-02-26 2024-02-05 B Purchase
2.7
Schneid Yair
Large shareholder
97,402 +1.3%
0.18
US$17,922 		97,402 +1.3% 0.18 US$17,922
2024-02-26 2024-01-30 B Purchase
2.7
Schneid Yair
Large shareholder
335,000 +4.6%
0.18
US$60,635 		335,000 +4.6% 0.18 US$60,635
2024-02-26 2024-01-29 B Purchase
2.7
Schneid Yair
Large shareholder
150,000 +2.1%
0.18
US$27,000 		150,000 +2.1% 0.18 US$27,000
2023-03-20 2023-03-16 B Purchase
3.2
Bachleda Mark

Chief Commercial Officer

Officer
11,000 +inf%
2.25
US$24,717 		11,000 +inf% 2.25 US$24,717
2023-03-14 2023-03-13 B Purchase
2.2
Degnan Chris

Chief Financial Officer

Officer
10,000 +inf%
1.96
US$19,593 		10,000 +inf% 1.96 US$19,593
2023-03-14 2023-03-10 B Purchase
2.6
Sorensen Mel

President and CEO

Executive Director
100,000 +43.1%
1.68
US$168,120 		100,000 +43.1% 1.68 US$168,120
2021-12-20 2021-12-17 B Purchase
2.7
West Linda
Non-Executive Director
20,000 +50.0%
2.74
US$54,804 		20,000 +50.0% 2.74 US$54,804
2021-09-03 2021-09-01 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
47,756 -100.0%
8.47
US$404,498 		47,756 -100.0% 8.47 US$404,498
2021-06-17 2021-06-15 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +33.3%
9.13
US$91,300 		10,000 +33.3% 9.13 US$91,300
2021-06-04 2021-06-02 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +50.0%
8.65
US$86,511 		10,000 +50.0% 8.65 US$86,511
2021-06-03 2021-06-01 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
4,045 +inf%
8.59
US$34,741 		4,045 +inf% 8.59 US$34,741
2021-06-02 2021-06-01 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +100.0%
8.64
US$86,381 		10,000 +100.0% 8.64 US$86,381
2021-06-02 2021-05-28 B Purchase
2.7
West Linda
Non-Executive Director
10,000 +inf%
8.64
US$86,410 		10,000 +inf% 8.64 US$86,410
2021-02-19 2021-02-18 S Sale
2.3
Novo Holdings A/S
Large shareholder
500,000 -16.9%
10.58
US$5,290,000 		500,000 -16.9% 10.58 US$5,290,000
2020-11-17 2020-11-13 B Purchase
1.8
Alleva Lawrence M
Non-Executive Director
2,325 +58.1%
10.22
US$23,771 		2,325 +58.1% 10.22 US$23,771
2020-11-16 2020-11-13 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.32
US$103,197 		10,000 -100.0% 10.32 US$103,197
2020-11-16 2020-11-12 S Sale
1.1
Sussman Joel F.

Chief Accounting Officer

Officer
10,000 -100.0%
10.06
US$100,627 		10,000 -100.0% 10.06 US$100,627
2020-10-28 2020-10-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,244 -100.0%
15.00
US$33,660 		2,244 -100.0% 15.00 US$33,660
2020-10-19 2020-10-15 S Sale
2.3
Novo Holdings A/S
Large shareholder
450,000 -13.2%
11.00
US$4,950,000 		450,000 -13.2% 11.00 US$4,950,000
2020-10-07 2020-10-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
10,536 -100.0%
12.00
US$126,432 		10,536 -100.0% 12.00 US$126,432
2020-10-07 2020-10-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
100 -100.0%
12.00
US$1,200 		100 -100.0% 12.00 US$1,200
2020-06-22 2020-06-19 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
1,001,312 -28.9%
8.25
US$8,260,824 		1,001,312 -28.9% 8.25 US$8,260,824
2020-06-22 2020-06-18 S Sale
2.7
Novartis Bioventures Ltd

Former 10% Owner
900 -0.0%
9.04
US$8,136 		900 -0.0% 9.04 US$8,136
2020-06-17 2020-06-17 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,622 -0.1%
9.27
US$42,846 		4,622 -0.1% 9.27 US$42,846
2020-06-17 2020-06-16 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,600 -0.2%
9.30
US$79,980 		8,600 -0.2% 9.30 US$79,980
2020-06-17 2020-06-15 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
6,164 -0.2%
9.05
US$55,784 		6,164 -0.2% 9.05 US$55,784
2020-06-12 2020-06-12 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
1,500 -0.0%
9.19
US$13,785 		1,500 -0.0% 9.19 US$13,785
2020-06-12 2020-06-11 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,200 -0.2%
9.21
US$66,312 		7,200 -0.2% 9.21 US$66,312
2020-06-12 2020-06-10 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,532 -0.2%
9.46
US$80,713 		8,532 -0.2% 9.46 US$80,713
2020-06-09 2020-06-09 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
7,000 -0.2%
9.38
US$65,660 		7,000 -0.2% 9.38 US$65,660
2020-06-09 2020-06-08 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,659 -0.2%
9.66
US$54,666 		5,659 -0.2% 9.66 US$54,666
2020-06-09 2020-06-05 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
8,652 -0.2%
9.66
US$83,578 		8,652 -0.2% 9.66 US$83,578
2020-06-04 2020-06-04 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
4,088 -0.1%
9.55
US$39,040 		4,088 -0.1% 9.55 US$39,040
2020-06-04 2020-06-03 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,208 -0.1%
9.78
US$50,934 		5,208 -0.1% 9.78 US$50,934
2020-06-04 2020-06-02 S Sale
2.7
Novartis Bioventures Ltd
Large shareholder
5,669 -0.2%
9.68
US$54,876 		5,669 -0.2% 9.68 US$54,876
2020-05-28 2020-05-26 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
692 -100.0%
12.00
US$8,304 		692 -100.0% 12.00 US$8,304
2020-05-22 2020-05-21 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,174 -100.0%
12.00
US$14,088 		1,174 -100.0% 12.00 US$14,088
2020-05-22 2020-05-20 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
969 -100.0%
12.00
US$11,628 		969 -100.0% 12.00 US$11,628
2020-05-12 2020-05-12 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
671 -100.0%
12.00
US$8,052 		671 -100.0% 12.00 US$8,052
2020-05-12 2020-05-11 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
185 -100.0%
12.00
US$2,220 		185 -100.0% 12.00 US$2,220
2020-05-12 2020-05-08 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
5,102 -100.0%
12.00
US$61,224 		5,102 -100.0% 12.00 US$61,224
2020-05-07 2020-05-07 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
2,059 -100.0%
12.00
US$24,709 		2,059 -100.0% 12.00 US$24,709
2020-05-07 2020-05-06 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
1,489 -100.0%
12.00
US$17,868 		1,489 -100.0% 12.00 US$17,868
2020-05-07 2020-05-05 PlS Planned sale
HOLMLUND JON T

Chief Medical Officer

Officer
3,064 -100.0%
12.16
US$37,258 		3,064 -100.0% 12.16 US$37,258
2019-12-17 2019-12-13 B Purchase Alleva Lawrence M Non-Executive Director
4,000 +inf%
9.78
US$39,139 		4,000 +inf% 9.78 US$39,139
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Clarus IV-A, L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-14 2019-11-12 B Purchase
2.3
Novo Holdings A/S

SEE REMARKS

Large shareholder
500,000 +17.2%
12.00
US$6,000,000 		500,000 +17.2% 12.00 US$6,000,000
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
19,423 +17.5%
12.00
US$233,076 		19,423 +17.5% 12.00 US$233,076
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
97,131 +17.5%
12.00
US$1,165,572 		97,131 +17.5% 12.00 US$1,165,572
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
52,660 +17.5%
12.00
US$631,920 		52,660 +17.5% 12.00 US$631,920
2019-11-14 2019-11-12 B Purchase
1.5
Blackstone Clarus GP L.P.
Large shareholder
80,786 +17.5%
12.00
US$969,432 		80,786 +17.5% 12.00 US$969,432
2019-11-12 2019-11-12 B Purchase Sofinnova Venture Partners IX, L.P. Large shareholder
750,000 +32.1%
12.00
US$9,000,000 		750,000 +32.1% 12.00 US$9,000,000
2019-11-12 2019-11-12 B Purchase New Enterprise Associates 14, L.P. Large shareholder
416,666 +10.6%
12.00
US$4,999,992 		416,666 +10.6% 12.00 US$4,999,992
2019-11-12 2019-11-12 B Purchase Novartis Bioventures Ltd Large shareholder
250,000 +7.6%
12.00
US$3,000,000 		250,000 +7.6% 12.00 US$3,000,000
Explore more

More insider trading research around Galera Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America